CXCL5 and prostate carcinoma: For example, CXCL5 is overexpressed in oral squamous cell carcinoma, colorectal cancer, hepatocellular cancer, prostate cancer, gastric cancer and pancreatic cancer [14]–[20], with overexpression being associated with poor patient survival [15]–[17].